What question did this study set out to answer?

This research aims to explore how inflammatory biomarkers can help diagnose metabolic syndrome and assess its severity.

April 19, 2026

Can the Diagnosis of Metabolic Syndrome and the Severity of the Disease Be Determined with the Help of Inflammatory Biomarkers?

Resultado clave

Fetuin-A and YKL-40 levels are strongly associated with the presence and short-term severity of metabolic syndrome, while hsCRP reflects longitudinal changes in metabolic burden.

Puntos clave

This research aims to explore how inflammatory biomarkers can help diagnose metabolic syndrome and assess its severity.
Measured levels of fetuin-A and YKL-40 in relation to metabolic syndrome presence and severity.
Monitored hsCRP levels to evaluate changes in metabolic burden over time.
Analyzed correlations between these biomarkers and metabolic syndrome dynamics.
Fetuin-A and YKL-40 levels correlate strongly with the presence and severity of metabolic syndrome.
hsCRP levels reflect changes in the metabolic burden over the short-term.
Findings indicate potential for using these biomarkers in clinical settings.

PICO estructurado

Do inflammatory biomarkers (Fetuin-A, YKL-40, hsCRP) correlate with the diagnosis and severity of Metabolic Syndrome?

Población

Patients evaluated for Metabolic Syndrome (MetS)

Intervención

Measurement of inflammatory biomarkers (Fetuin-A, YKL-40, hsCRP)

Resultado

Presence and severity of Metabolic Syndromesurrogate

Fetuin-A, YKL-40, and hsCRP may serve as useful biomarkers for tracking the severity and longitudinal metabolic burden of Metabolic Syndrome.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Fetuin-A and YKL-40 levels are strongly associated with both the presence and short-term changes in MetS severity. hsCRP appears to reflect longitudinal changes in metabolic burden. These findings suggest that selected inflammatory biomarkers may provide additional insight into the inflammatory and metabolic dynamics of MetS.

Me gusta

Guardar